Honghe Hani And Yi Autonomous Prefecture

Researchers are evaluating the use of artificial intelligence-driven virtual standardized patients VSPs to improve the ability of primary care doctors in China to manage common pediatric diseases. The study addresses challenges in Chinas pediatric healthcare system, including limited capacity in primary care and a lack of effective training tools. It involves a randomized controlled trial with over 459 doctors from various specialties across more than 10 provinces, aiming to enhance pediatric care through innovative training methods. The trial involves three groups one using a virtual patient platform where doctors interact with AI-driven simulated patients covering diseases like pneumococcal pneumonia, rotavirus enteritis with hypovolemic shock, hand-foot-and-mouth disease, acute appendicitis, and respiratory failure another group uses case teaching manuals, and the third group uses case teaching videos. Participants engage in a two-week learning period with their assigned training method. During the study, doctors management skills will be assessed through clinical vignettes to measure adherence to best clinical practice guidelines. Researchers will monitor diagnosis accuracy, examination scores relevant to disease handling, and doctors focus on patient needs. The study runs for about six months and includes over 300 primary healthcare institutions to ensure wide representation. The trial also evaluates the acceptance and costs of the training methods used.

Researchers are studying cardiovascular diseases CVD including coronary heart disease, atrial fibrillation, and chronic heart failure in participants aged 40 years or older. The study aims to describe how common chronic obstructive pulmonary disease COPD is among these participants and to observe how combined heart and lung care affects their short-term health outcomes. Approximately 3,000 participants will be enrolled, with about 1,000 in each disease group. The study uses a behavioral intervention that includes guideline education and implementation at both the investigator and patient levels. Investigators receive disease education before enrollment, and cardiologists and pulmonologists provide ongoing disease education and coordinated treatment every four weeks. Participants will be followed up every four weeks to manage their care and monitor progress. Participants will undergo spirometry testing and complete questionnaires to assess their lung and heart health. Researchers will measure COPD prevalence, hospitalization rates, symptom scores, lung function, and other heart and lung-related biomarkers over 12 weeks. The study includes assessments of treatment adherence and changes in health status through repeated evaluations at baseline and weeks 4, 8, and 12. Safety and outcomes will be closely monitored throughout the study period.